Lisata Therapeutics merges with Marea Therapeutics in reverse merger after failed Kuva deal
Lisata Therapeutics, a solid tumor biotech, announced a stock-for-stock merger with cardiovascular specialist Marea Therapeutics after a previous merger attempt with Kuva Labs collapsed.
The transaction resembles a reverse merger, giving Marea's existing investors about 59.5% of the combined company, Lisata shareholders about 2.4%, and investors in a $225 million private placement the remaining stake.
The merged entity will focus on advancing Marea's phase-2 candidates MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly, with topline data expected in the fourth quarter.
The private placement attracted backing from RA Capital Management, Forbion, Third Rock Ventures and Sofinnova Investments.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “After one failed acquisition attempt, Lisata finds lifeline in Marea merger”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that